News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Almirall Licenses Aclidinium to Invida in Australia and New Zealand



10/10/2012 8:47:09 AM

BARCELONA, Spain & SINGAPORE--(BUSINESS WIRE)--Almirall (ALM:MC) and Invida Holdings Private Limited, a member of the Menarini Group, are pleased to announce that Almirall has granted Invida commercial rights for Aclidinium in Australia and New Zealand for the treatment of COPD. Financial details of the agreement have not been disclosed. The agreement includes both Aclidinium monotherapy and its combination with Formoterol. Invida, as a leading pharmaceutical commercialization company in Asia-Pacific, is committed to bringing innovative drugs and pharmaceutical research to doctors and patients in the region. Invida will be responsible for marketing the novel compound in Australia and New Zealand, both to primary and specialty care physicians.

Read at BioSpace.com


comments powered by Disqus
Almirall
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES